Biosimilar ustekinumab CT-P43
Milan Lukáš1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. ClinicalTrial.gov. Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects. 2021 [online]. Dostupné z: https://clinicaltrials.gov/study/NCT04428814?term=CT-P43& checkSpell=false&rank=2.
2. ClinicalTrial.gov. A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis. 2023 [online]. Dostupné z: https://clinicaltrials.gov/study/NCT04673786?term=CT-P43&checkSpell=false&rank=1.
3. Papp KA, Lebwohl MG, Thaci D et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28 week results of a randomized, active controlled, double blind, phase III study. BioDrugs 2024; 38(1): 121–131. doi: 10.1007/s40259-023-00630-5.